Xu ZJ, Wei MJ, Zhang XM, Liu HG, Wu JP, Huang JF, Li YF, Huang ZJ, Yan YY. Effects of microwave ablation on serum Golgi protein 73 in patients with primary liver cancer. World J Gastroenterol 2022; 28(29): 3971-3980 [PMID: 36157538 DOI: 10.3748/wjg.v28.i29.3971]
Corresponding Author of This Article
Zheng-Ju Xu, MD, Chief Doctor, The Liver Disease Center, The 910th Hospital of the PLA Joint Logistics Support Force, No. 180 Huayuan Road, Fengze District, Quanzhou 362000, Fujian Province, China. h180@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Xu ZJ, Wei MJ, Zhang XM, Liu HG, Wu JP, Huang JF, Li YF, Huang ZJ, Yan YY. Effects of microwave ablation on serum Golgi protein 73 in patients with primary liver cancer. World J Gastroenterol 2022; 28(29): 3971-3980 [PMID: 36157538 DOI: 10.3748/wjg.v28.i29.3971]
Zheng-Ju Xu, Hui-Guo Liu, Jin-Piao Wu, Jin-Fa Huang, Yong-Fei Li, Zhi-Jie Huang, Yan-Yan Yan, The Liver Disease Center, The 910th Hospital of the PLA Joint Logistics Support Force, Quanzhou 362000, Fujian Province, China
Mei-Juan Wei, Central Laboratory, Decheng Hospital, Quanzhou 362104, Fujian Province, China
Xiao-Man Zhang, Central Laboratory of Clinical Hepatology, The 910th Hospital of the PLA Joint Logistics Support Force, Quanzhou 362000, Fujian Province, China
Author contributions: Xu ZJ carried out the design, coordination of experimental work, manuscript writing, and also performed the microwave ablation procedure; Wei MJ and Zhang XM participated in the study design and data analysis; Liu HG, Wu JP, Huang JF, Li YF, Huang ZJ, and Yan YY participated in data collection and analysis; all authors read and approved the final manuscript.
Supported bythe Military Medical Science and Technology Committee of China, No. 14MS095; and the Quanzhou Science and Technology Planning Project, No. 2017Z018.
Institutional review board statement: The study was reviewed and approved by the 910th Hospital of the PLA Joint Logistics Support Force Institutional Review Board.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: Xu ZJ has received research funding from the Military Medical Science and Technology Committee of China, No. 14MS095, and grants from the Quanzhou Science and Technology Planning Project, No. 2017Z018, during the conduct of the study.
Data sharing statement: Technical appendix and dataset available from the corresponding author at " h180@163.com". Participants gave informed consent for data sharing.
Corresponding author: Zheng-Ju Xu, MD, Chief Doctor, The Liver Disease Center, The 910th Hospital of the PLA Joint Logistics Support Force, No. 180 Huayuan Road, Fengze District, Quanzhou 362000, Fujian Province, China. h180@163.com
Received: February 21, 2022 Peer-review started: February 21, 2022 First decision: April 16, 2022 Revised: April 30, 2022 Accepted: July 5, 2022 Article in press: July 5, 2022 Published online: August 7, 2022 Processing time: 163 Days and 4.8 Hours
ARTICLE HIGHLIGHTS
Research background
Microwave ablation (MWA) has been proven to be highly effective in treatment of small primary liver cancer. However, the procedure may trigger an inflammatory response and cause liver injury in primary liver cancer patients undergoing MWA. As such, it is needed to find reliable markers to monitor and evaluate patient response to MWA. Previous studies have shown that Golgi protein 73 (GP73) are associated with liver inflammatory injury.
Research motivation
This study was designed to test our hypothesis that serum GP73 levels altered in response to MWA in patients with primary liver cancer, and thereby could be used as a potential marker for MWA-induced liver inflammation and injury.
Research objectives
The main objective of this study was to examine effects of MWA on the serum levels of GP73 before and at different time points after the ablation procedure in patients with primary liver cancer.
Research methods
Patients with primary liver cancer (≤ 3 cm in diameter) receiving MWA were retrospectively enrolled in this study. Serum GP73 levels were compared before and 1, 2, and 4 wk after the ablation procedure.
Research results
The serum GP73 levels were significantly elevated at 1 and 2 wk after MWA with the peak at 2 wk after completion of the treatment. The serum GP73 levels decreased starting at 4 wk after MWA and continued to decline to the pretreatment level at 12 and 24 wk after MWA. It was worthy to note that the alterations of serum GP73 levels in response to MWA were similar to those of liver biochemical indicators.
Research conclusions
The findings of this study have demonstrated that serum GP73 levels altered in response to MWA in patients with primary liver cancer, and thereby measurement of serum GP73 level holds potential as a biomarker for monitoring and assessment of MWA-mediated inflammatory injury in patients with primary liver cancer.
Research perspectives
Future prospective studies are needed to validate the findings and to assess the diagnostic accuracy of serum GP73 for monitoring liver injury following MWA treatment for primary liver cancer.
